RecruitingPhase 1Phase 2NCT06778850

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

A Randomized, Double-blind, Placebo-controlled Phase I/IIa Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MDR-001 Tablets Administrated Orally in Healthy Participants and Obese/ Overweight Participants

Sponsor

MindRank AI Ltd

Enrollment

131 participants

Start Date

Jun 9, 2023

Study Type

INTERVENTIONAL

Conditions

Overweight and Obese Volunteers

Summary

To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MDR-001 and a drug called palcebo for people with overweight and obese volunteers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMDR-001

Oral administration of small molecule MDR-001 tablets

DRUGpalcebo

Administered orally placebo

Locations(1)

The first hospital of Jilin University

Changchun, Jilin, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06778850

Related Trials

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

NCT064930841 location